What is Tecentriq’s “patent cliff”?
Tecentriq (atezolizumab) has faced a growing risk window as parts of its intellectual property approach expiry, creating the conditions for companies to pursue generics or biosimilar launches once legal barriers fall. The “patent cliff” is the point where multiple patents and related exclusivity protections no longer block competitors, which typically leads to price competition and loss of market exclusivity.
DrugPatentWatch tracks patent/exclusivity status for Tecentriq and is one of the quickest ways to see when key protections are expected to end. You can check Tecentriq’s patent timeline here: https://www.drugpatentwatch.com/p/tecents
When would Tecentriq exclusivity/patent protection end?
The exact “cliff” depends on which jurisdiction you’re talking about (for example, U.S. vs. EU) and which type of protection is expiring (primary patents vs. follow-on patents vs. exclusivity/other IP barriers). DrugPatentWatch compiles these dates and patent events in one place, which is usually what people mean by “the patent cliff” for a branded biologic like Tecentriq.
Why does the “Tecentriq patent cliff” matter for pricing and competition?
Once major patent protections expire, biosimilar (or other legally available) pathways can open. For patients and payers, that often means:
- more contracting pressure and discounts from the reference product
- increased availability of lower-cost alternatives over time (subject to approvals and uptake)
- shifts in market share as biosimilars enter
What competitors or biosimilar threats typically drive a patent cliff?
For biologics, the patent cliff is usually tied to biosimilar development strategies. Competitors often look to:
- challenge or design around specific patents
- seek regulatory approval in countries where exclusivity barriers have ended
- launch quickly once litigation and exclusivity constraints are cleared
How can I pinpoint the exact “cliff” for my country?
If you tell me the country (U.S., EU, UK, etc.), I can help you interpret what DrugPatentWatch lists there and translate it into “earliest likely competitive entry” vs. “true last exclusivity date.”
Sources
- DrugPatentWatch – Tecentriq (atezolizumab)